Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 20 years of age or older~* Diagnosis of POAG or OHT in both eyes (POAG in one eye and OHT in the fellow eye was acceptable)~* Medicated intraocular pressure (IOP) ≥ 14 mmHg in at least one eye and \< 30 mmHg in both eyes at screening visit~* For POAG eyes, unmedicated (post washout) IOP ≥ 15 mmHg and \< 35 mmHg in the study eye at 2 qualification visits (09:00 hours), 2-7 days apart. At second qualification visit IOP ≥ 15 mmHg and \< 35 mmHg at 11:00 and 16:00 hour (in the same eye).~* For OHT eyes, unmedicated (post washout) IOP ≥ 22 mmHg and \< 35 mmHg in the study eye at 2 qualification visits (09:00 hours), 2-7 days apart. At second qualification visit IOP ≥ 22 mmHg and \< 35 mmHg at 11:00 and 16:00 hours (in the same eye)~* Best-corrected visual acuity (BCVA) +0.7 log MAR or better (20/100 Snellen or better or 0.20 or better in decimal unit) in each eye~* Willingness and ability to give signed informed consent and follow study instructions~Exclusion Criteria:~* Clinically significant ocular disease~* Retinal diseases that may progress during the study period~* Pseudoexfoliation or pigment dispersion component glaucoma, history of angle closure glaucoma, or narrow angles~* Previous glaucoma intraocular surgery~* Refractive surgery in either eye~* Ocular hyperemia score of moderate (+2) or severe (+3) at Qualification Visit #2~* Ocular trauma~* Ocular infection or inflammation~* Any corneal disease that may confound assessment~* Evidence of corneal deposits or cornea verticillata~* Known hypersensitivity to any component of netarsudil ophthalmic solution 0.02%, ripasudil hydrochloride hydrate ophthalmic solution 0.4%, or to topical anesthetic.~* Mean central corneal thickness \>620 um~* Any abnormality preventing reliable Goldmann applanation tonometry of either eye (e.g. keratoconus)~* Cannot demonstrate proper delivery of the eye drop~* Clinically significant systemic disease~* Participation in any investigational study within 30 days prior to screening~* Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Netarsudil ophthalmic solution 0.02% and netarsudil ophthalmic solution vehicle (Type: EXPERIMENTAL): 1 drop netarsudil 0.02% in the evening and 1 drop netarsudil vehicle in the morning in each eye.
- Ripasudil hydrochloride hydrate ophthalmic solution 0.4% (Type: ACTIVE_COMPARATOR): 1 drop ripasudil twice daily in the morning and evening in each eye.

Based on this trial design, predict the completion outcome and termination type (if applicable).